Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi

Joint Meeting of Chuikyo Subcommittees on Drug Pricing, CEA A key Japanese reimbursement policy council on November 15 hammered out a policy for the initial price-setting and post-launch re-pricing of Eisai’s Alzheimer’s therapy Leqembi (lecanemab). According to the policy, the...read more